Daiichi of Japan saw its operating profits in the fiscal year ended March 31, 1996, advance 7.3% to 41 billion yen ($37.8 million), recurring profits were 42.8 billion yen, up 2.6%, and net profits were flat at 20.5 billion yen. Earnings per share were flat at 75.40 yen.
Sales for the year were 217.3 billion yen, an increase of 2.6% on the previous 12 months. The company is expecting turnover in the current fiscal year of its imaging agent Omnipaque (iohexol) to fall sharply as a result of the Japanese government price cuts being implemented, but is pinning its hopes on new products it is introducing during the year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze